UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024
Rhea-AI Summary
Utah Medical Products (Nasdaq: UTMD) reported a substantial decline in revenues for 2Q and 1H 2024 compared to the same periods in 2023. 2Q 2024 revenues were $2,466 (19.2%) lower, and 1H 2024 revenues were $3,646 (14.4%) lower. Major contributors to the decline include reduced sales in three categories: PendoTech OEM, China BPM Distributor, and Filshie Clip System.
Despite the revenue drop, UTMD maintained similar profit margins: Gross Profit Margin remained at 60.1% for 2Q 2024. However, Operating Income and Net Income declined by 22% and 18% respectively for 2Q 2024.
The balance sheet remains strong with $89.2 million in cash and no debt. The company paid $2.2 million in dividends and repurchased $9.4 million of its common stock during 1H 2024. UTMD expects a similar magnitude of revenue decline in the remaining quarters of 2024.
Positive
- Maintained a strong gross profit margin of 60.1% in 2Q 2024 despite a 19.2% drop in revenues.
- Strong balance sheet with $89.2 million in cash and no debt.
- Significant share repurchases ($9.4 million) during 1H 2024.
Negative
- 2Q 2024 revenues were $2,466 (19.2%) lower than 2Q 2023.
- 1H 2024 revenues were $3,646 (14.4%) lower than 1H 2023.
- Significant decline in sales to PendoTech OEM customer, impacting overall revenue.
- Operating Income fell by 22% in 2Q 2024.
- Net Income declined by 18% in 2Q 2024.
- Higher litigation costs impacting Operating Expenses.
News Market Reaction
On the day this news was published, UTMD declined 6.09%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues.
Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.
Overview of Results
In brief, consolidated total 2Q 2024 revenues were
Revenue Category |
| Portion of 2Q Lower Total UTMD Sales |
| Portion of 1H Lower Total UTMD Sales | ||||
WW PendoTECH OEM |
|
| 70 | % |
|
| 76 | % |
China BPM Distributor |
|
| 21 | % |
|
| 12 | % |
WW Filshie Clip System |
|
| 16 | % |
|
| 25 | % |
Total: |
|
| 107 | % |
|
| 113 | % |
In other words, aggregated consolidated sales in all other sales categories were higher when comparing 2024 to 2023 in both periods. Please see more details explaining revenue results below.
Despite the significantly lower sales, UTMD achieved profit margins in all income categories similar to those of the prior year's same periods:
| 2Q 2024 (Apr - Jun) |
|
| 2Q 2023 (Apr - Jun) |
|
| 1H 2024 (Jan - Jun) |
|
| 1H 2023 (Jan - Jun) |
| |||||
Gross Profit Margin (GP/ sales): |
|
| 60.1 | % |
|
| 60.1 | % |
|
| 59.9 | % |
|
| 61.4 | % |
Operating Income Margin (OI/ sales): |
|
| 33.1 | % |
|
| 34.4 | % |
|
| 33.7 | % |
|
| 34.9 | % |
Income B4 Tax Margin (EBT/ sales): |
|
| 40.5 | % |
|
| 40.2 | % |
|
| 41.4 | % |
|
| 40.5 | % |
Net Income Margin (NI/ sales): |
|
| 33.2 | % |
|
| 32.6 | % |
|
| 34.1 | % |
|
| 33.1 | % |
A summary of the change in income statement results, according to U.S. Generally Accepted Accounting Principles (US GAAP), follows:
| 2Q |
| 1H | |||||
Revenues (Sales): |
|
| (19) | % |
|
| (14) | % |
Gross Profit (GP): |
|
| (19) | % |
|
| (16) | % |
Operating Income (OI): |
|
| (22) | % |
|
| (17) | % |
Income Before Tax (EBT): |
|
| (19) | % |
|
| (12) | % |
Net Income (NI): |
|
| (18) | % |
|
| (12) | % |
Earnings Per Share (EPS): |
|
| (15) | % |
|
| (11) | % |
The percentage decline in 2Q consolidated revenues was greater than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer increased from
UTMD's June 30, 2024 Balance Sheet continued strong, with no debt. Ending Cash and Investments were
Revenues (sales) -2Q 2024
Total consolidated 2Q 2024 UTMD worldwide (WW) sales in USD terms were
Consistent with the projection in UTMD's SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD's previously largest OEM customer, PendoTECH, invoiced by both the U.S. and Ireland, were
The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since they tend to order large quantities at a time in order to minimize transit and other logistical costs. The second major revenue decline category, which was also as projected in UTMD's 2024 SEC 10-K Report, was due to shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD's largest BPM medical device distributor located in China. This customer consistently places calendar year fixed orders with UTMD. In 2Q 2024, sales were
With a high level of uncertainty, UTMD projected maintaining Filshie Clip System device (Filshie) sales in 2024 similar to 2023. This was the third major category responsible for lower sales. WW consolidated Filshie sales in 2Q 2024 were
In sum, the 2Q 2024 decline in sales from the three categories above compared to 2Q 2023 was
In 2Q 2024 compared to 2Q 2023, outside the U.S. (OUS) sales were
The portion of OUS sales invoiced in foreign currencies in USD terms were
| 2Q 2024 |
|
| 2Q 2023 |
|
| Change |
|
| ||||
GBP |
|
| 1.2615 |
|
|
| 1.2531 |
|
|
| 0.7 | % |
|
EUR |
|
| 1.0752 |
|
|
| 1.0845 |
|
|
| (0.9) | % |
|
AUD |
|
| 0.6594 |
|
|
| 0.6700 |
|
|
| (1.6) | % |
|
CAD |
|
| 0.7308 |
|
|
| 0.7449 |
|
|
| (1.9) | % |
|
The
Total OUS sales in 2Q 2024 were
Domestic U.S. sales in 2Q 2024 were
Sales -1H 2024
Total consolidated 1H 2024 UTMD WW sales in USD terms were
Consistent with the projection in UTMD's SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD's previously largest OEM customer, PendoTECH, invoiced by both the U.S. and Ireland, were
The second major revenue decline category, which was also as projected in UTMD's 2024 SEC 10-K Report, was due to shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD's largest BPM medical device distributor located in China. In 1H 2024, sales were
With a high level of uncertainty, UTMD projected maintaining Filshie Clip System device (Filshie) sales in 2024 similar to 2023. This was the third major category responsible for lower 1H sales. WW consolidated Filshie sales in 1H 2024 were
In sum, the 1H 2024 decline in sales from the three categories above compared to 1H 2023 was
Total OUS sales in 1H 2024 were
| 1H 2024 |
|
| 1H 2023 |
|
| Change |
|
| ||||
GBP |
|
| 1.2646 |
|
|
| 1.2329 |
|
|
| 2.6 | % |
|
EUR |
|
| 1.0787 |
|
|
| 1.0819 |
|
|
| (0.3) | % |
|
AUD |
|
| 0.6586 |
|
|
| 0.6774 |
|
|
| (2.8) | % |
|
CAD |
|
| 0.7362 |
|
|
| 0.7419 |
|
|
| (0.8) | % |
|
The weighted-average FX rate positive impact on 1H 2024 foreign currency OUS sales was
Direct to end-user OUS 1H 2024 sales in USD terms (including the impact of FX rate differences) were
Domestic U.S. sales in 1H 2024 were
Gross Profit (GP)
GP results from subtracting the cost of goods sold (CGS), comprised of costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing including freight for receiving materials from suppliers, from revenues. CGS is divided into three categories: direct labor, raw materials and manufacturing overhead (MOH). Direct labor and raw materials are predominantly variable costs, i.e. vary directly with revenues. MOH contains many fixed costs consistent with the Company's infrastructure, for example, supervision and engineering personnel.
UTMD's 2Q 2024 GP was
With lower sales and consequent lower absorption of fixed MOH costs, a higher than expected average GPM was achieved through several means; 1) a favorable product sales mix, i.e. lower sales to UTMD's China distributor at UTMD's lowest GPM, 2) a direct labor productivity improvement as the least experienced production workers were furloughed, 3) reduction of some production supervision and management, 4) relief in marginal costs of some raw materials, 5) substantially lower incoming freight costs from raw material vendors, and 6) a reduction in intercompany finished goods inventory which freed up reserved gross profit.
Operating Income (OI)
OI results from subtracting Operating Expenses (OE) from GP. OE are comprised of Sales and Marketing (S&M) expenses, General and Administrative (G&A) expenses and Product Development (R&D) expenses.
OI in 2Q 2024 of
OI in 1H 2024 was
The following table summarizes OE in 2Q and 1H 2024 compared to the same periods in 2023 by OE category:
OE Category |
| 2Q 2024 |
| % of sales |
| 2Q 2023 |
| % of sales |
| 1H 2024 |
| % of sales |
| 1H 2023 |
| % of sales |
| ||||||||
S&M: |
| $ | 546 |
|
| 5.3 |
| $ | 405 |
|
| 3.2 |
| $ | 958 |
|
| 4.4 |
| $ | 792 |
|
| 3.1 |
|
G&A: |
|
| 2,014 |
|
| 19.4 |
|
| 2,775 |
|
| 21.6 |
|
| 4,219 |
|
| 19.4 |
|
| 5,648 |
|
| 22.3 |
|
R&D: |
|
| 255 |
|
| 2.4 |
|
| 133 |
|
| 1.0 |
|
| 520 |
|
| 2.4 |
|
| 277 |
|
| 1.1 |
|
Total OE: |
|
| 2,815 |
|
| 27.1 |
|
| 3,313 |
|
| 25.8 |
|
| 5,697 |
|
| 26.2 |
|
| 6,717 |
|
| 26.5 |
|
S&M OE were
G&A expenses dominate UTMD's OE, largely because of non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System and the expenses of current litigation in the U.S. A segmentation of USD-denominated G&A expenses follows:
G&A Exp Category |
| 2Q 2024 |
| % of sales |
| 2Q 2023 |
| % of sales |
| 1H 2024 |
| % of sales |
| 1H 2023 |
| % of sales |
| ||||||||
IIA Amort- UK: |
| $ | 501 |
|
| 4.8 |
| $ | 498 |
|
| 3.9 |
| $ | 1,005 |
|
| 4.6 |
| $ | 981 |
|
| 3.9 |
|
IIA Amort- CSI: |
|
| - |
|
|
|
|
| 1,105 |
|
| 8.6 |
|
| - |
|
|
|
|
| 2,210 |
|
| 8.7 |
|
Other- UK: |
|
| 173 |
|
|
|
|
| 163 |
|
|
|
|
| 360 |
|
|
|
|
| 327 |
|
|
|
|
U.S. Litigation |
|
| 635 |
|
| 6.1 |
|
| 280 |
|
| 2.2 |
|
| 1,378 |
|
| 6.3 |
|
| 689 |
|
| 2.7 |
|
Other- US: |
|
| 557 |
|
| 5.4 |
|
| 588 |
|
| 4.6 |
|
| 1,158 |
|
| 5.3 |
|
| 1,150 |
|
| 4.5 |
|
IRE: |
|
| 92 |
|
|
|
|
| 69 |
|
|
|
|
| 186 |
|
|
|
|
| 153 |
|
|
|
|
AUS: |
|
| 24 |
|
|
|
|
| 35 |
|
|
|
|
| 66 |
|
|
|
|
| 69 |
|
|
|
|
CAN: |
|
| 32 |
|
|
|
|
| 37 |
|
|
|
|
| 66 |
|
|
|
|
| 69 |
|
|
|
|
Total G&A: |
|
| 2,014 |
|
| 19.4 |
|
| 2,775 |
|
| 21.6 |
|
| 4,219 |
|
| 19.4 |
|
| 5,648 |
|
| 22.2 |
|
Total consolidated G&A expenses in 2Q 2024 were
The differences in period-to-period R&D expenses were due to extensive outside material validation studies in 2024 required by biopharmaceutical industry manufacturers for devices used in their manufacturing processes. Since all R&D in 2024 was carried out in the U.S., there was no FX rate impact.
The impact of differing FX rates in 2024 and 2023 on OE expressed in USD was negligible. The EUR, AUD and CAD were all slightly weaker, but an average stronger GBP helped increase foreign currency OE when converted to USD by a net
OE Category |
| 2Q 2024 const FX |
|
| 2Q 2023 |
|
| 1H 2024 const FX |
|
| 1H 2023 |
| ||||
S&M: |
| $ | 547 |
|
| $ | 405 |
|
| $ | 958 |
|
| $ | 792 |
|
G&A: |
|
| 2,011 |
|
|
| 2,775 |
|
|
| 4,189 |
|
|
| 5,648 |
|
R&D: |
|
| 255 |
|
|
| 133 |
|
|
| 520 |
|
|
| 277 |
|
Total OE: |
|
| 2,813 |
|
|
| 3,313 |
|
|
| 5,667 |
|
|
| 6,717 |
|
Income Before Tax (EBT)
EBT results from subtracting net non‑operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 2Q 2024 EBT was
NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms on June 30, 2024; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company's technology. Starting in 2024 for UTMD, there is an additional excise tax included in NOE: a stock repurchase excise tax included in the so-called "Inflation Reduction Act of 2022". Although the new
Net NOI is NOI minus NOE. Net NOI in 2Q 2024 was
EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD's ongoing excellent financial operating performance, as well as its ability to sustain high level financial performance during a challenging time.
Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2024 consolidated EBT excluding the remeasured bank balance currency gain or loss ("adjusted consolidated EBITDA") was
UTMD's non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:
| 2Q 2024 |
|
| 2Q 2023 |
|
| 1H 2024 |
|
| 1H 2023 |
| |||||
EBT |
| $ | 4,211 |
|
| $ | 5,172 |
|
| $ | 9,010 |
|
| $ | 10,291 |
|
Depreciation Expense |
|
| 172 |
|
|
| 155 |
|
|
| 327 |
|
|
| 310 |
|
Femcare IIA Amortization Expense |
|
| 501 |
|
|
| 498 |
|
|
| 1,005 |
|
|
| 981 |
|
CSI IIA Amortization Expense |
|
| - |
|
|
| 1,105 |
|
|
| - |
|
|
| 2,211 |
|
Other Non-Cash Amortization Expense |
|
| 8 |
|
|
| 8 |
|
|
| 18 |
|
|
| 16 |
|
Stock Option Compensation Expense |
|
| 52 |
|
|
| 50 |
|
|
| 130 |
|
|
| 100 |
|
Interest Expense |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
Remeasured Foreign Currency Balances |
|
| (2 | ) |
|
| 8 |
|
|
| (1 | ) |
|
| 7 |
|
UTMD non-US GAAP EBITDA: |
| $ | 4,942 |
|
| $ | 6,996 |
|
| $ | 10,489 |
|
| $ | 13,916 |
|
Net Income (NI)
NI in 2Q 2024 of
NI in 1H 2024 of
The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. Except for the UK, in which the corporate income tax rate changed to
Earnings per share (EPS)
Diluted EPS in 2Q 2024 were
Diluted shares were 3,531,572 in 2Q 2024 compared to 3,638,566 in 2Q 2023. Diluted shares were 3,579,435 in 1H 2024 compared to 3,637,715 in 1H 2023. The lower diluted shares in both periods of 2024 were the result of shares repurchased during 1H 2024, offset by employee options exercised and a dilution factor for unexercised options just in 2023. Because the average exercise price of employee options was higher than the ending market price of the stock in 2Q 2024, the number of shares added as a dilution factor in 2Q 2024 was zero compared to 10,288 in 2Q 2023. For the same reason, the number of shares added as a dilution factor in 1H 2024 was zero compared to 9,660 in 1H 2023. The number of shares used for calculating EPS in both years was higher than period-ending outstanding shares because of a time-weighted calculation of average outstanding shares, plus dilution in 2023 from unexercised employee options.
Outstanding shares at the end of 2Q 2024 were 3,498,902 compared to 3,629,525 at the end of calendar year 2023. The difference was due to 7,592 shares added from employee option exercises during 1H 2024 and 138,215 shares subtracted from repurchases in 1H 2024. Share repurchases in 2Q 2024 were 95,107 shares at an average price of
The total number of outstanding unexercised employee and outside director options at June 30, 2024 was 73,497 at an average exercise price of
UTMD paid
UTMD's closing share price at the end of 2Q 2024 was
Balance Sheet.
At June 30, 2024 compared to the end of 2023, UTMD's cash and investments balance declined only
Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2024 compared to the end of calendar year 2023 and the end of 2Q 2023 were
| 6-30-24 |
| 12-31-23 |
| Change |
| 6-30-23 |
| Change |
| ||||||
GBP |
|
| 1.26371 |
|
| 1.27386 |
|
| (0.8) | % |
| 1.27084 |
|
| (0.6) | % |
EUR |
|
| 1.07109 |
|
| 1.10593 |
|
| (3.2) | % |
| 1.09178 |
|
| (1.9) | % |
AUD |
|
| 0.66742 |
|
| 0.68248 |
|
| (2.2) | % |
| 0.66614 |
|
| 0.2 | % |
CAD |
|
| 0.73068 |
|
| 0.75733 |
|
| (3.5) | % |
| 0.75547 |
|
| (3.3) | % |
Financial ratios as of June 30, 2024 which may be of interest to stockholders follow:
Current Ratio = 26.0
Days in Trade Receivables (based on 2Q 2024 sales activity) = 32
Average Inventory Turns (based on 2Q 2024 CGS) = 1.8
2024 YTD ROE (before dividends) =
12%
Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company's ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD's public disclosure filings with the SEC.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.
Utah Medical Products, Inc.
INCOME STATEMENT, Second Quarter (three months ended June 30)
(in thousands except earnings per share):
| 2Q 2024 |
|
| 2Q 2023 |
|
| Percent Change |
| ||||
Net Sales |
| $ | 10,400 |
|
| $ | 12,866 |
|
|
| (19.2) | % |
Gross Profit |
|
| 6,253 |
|
|
| 7,739 |
|
|
| (19.2) | % |
Operating Income |
|
| 3,438 |
|
|
| 4,425 |
|
|
| (22.3) | % |
Income Before Tax |
|
| 4,211 |
|
|
| 5,172 |
|
|
| (18.6) | % |
Net Income |
|
| 3,453 |
|
|
| 4,200 |
|
|
| (17.8) | % |
Earnings Per Share |
| $ | 0.978 |
|
| $ | 1.154 |
|
|
| (15.3) | % |
Shares Outstanding (diluted) |
|
| 3,532 |
|
|
| 3,639 |
|
|
|
|
|
INCOME STATEMENT, First Half (six months ended June 30)
(in thousands except earnings per share):
| 1H 2024 |
|
| 1H 2023 |
|
| Percent Change |
| ||||
Net Sales |
| $ | 21,740 |
|
| $ | 25,386 |
|
|
| (14.4) | % |
Gross Profit |
|
| 13,018 |
|
|
| 15,581 |
|
|
| (16.4) | % |
Operating Income |
|
| 7,321 |
|
|
| 8,864 |
|
|
| (17.4) | % |
Income Before Tax |
|
| 9,010 |
|
|
| 10,291 |
|
|
| (12.5) | % |
Net Income |
|
| 7,409 |
|
|
| 8,414 |
|
|
| (11.9) | % |
Earnings Per Share |
| $ | 2.070 |
|
| $ | 2.313 |
|
|
| (10.5) | % |
Shares Outstanding (diluted) |
|
| 3,579 |
|
|
| 3,637 |
|
|
|
|
|
BALANCE SHEET
(in thousands) |
| (unaudited) JUN 30, 2024 |
|
| (unaudited) MAR 31, 2024 |
|
| (audited) DEC 31, 2023 |
|
| (unaudited) JUN 30, 2023 |
| ||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Cash & Investments |
| $ | 89,219 |
|
| $ | 93,808 |
|
| $ | 92,868 |
|
| $ | 84,619 |
|
Accounts & Other Receivables, Net |
|
| 3,668 |
|
|
| 3,591 |
|
|
| 3,391 |
|
|
| 3,603 |
|
Inventories |
|
| 9,058 |
|
|
| 9,240 |
|
|
| 9,582 |
|
|
| 10,118 |
|
Other Current Assets |
|
| 377 |
|
|
| 510 |
|
|
| 428 |
|
|
| 467 |
|
Total Current Assets |
|
| 102,322 |
|
|
| 107,149 |
|
|
| 106,269 |
|
|
| 98,807 |
|
Property & Equipment, Net |
|
| 10,194 |
|
|
| 10,266 |
|
|
| 10,552 |
|
|
| 10,541 |
|
Intangible Assets, Net |
|
| 17,516 |
|
|
| 18,026 |
|
|
| 18,637 |
|
|
| 21,127 |
|
Total Assets |
| $ | 130,032 |
|
| $ | 135,441 |
|
| $ | 135,458 |
|
| $ | 130,475 |
|
Liabilities & Stockholders' Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts Payable |
|
| 834 |
|
|
| 998 |
|
|
| 769 |
|
|
| 1,336 |
|
REPAT Tax Payable |
|
| 558 |
|
|
| 558 |
|
|
| 558 |
|
|
| 419 |
|
Other Accrued Liabilities |
|
| 2,547 |
|
|
| 3,918 |
|
|
| 3,383 |
|
|
| 3,389 |
|
Total Current Liabilities |
| $ | 3,939 |
|
| $ | 5,474 |
|
| $ | 4,710 |
|
| $ | 5,144 |
|
Deferred Tax Liability - Intangible Assets |
|
| 860 |
|
|
| 986 |
|
|
| 1,120 |
|
|
| 1,370 |
|
Long Term Lease Liability |
|
| 275 |
|
|
| 285 |
|
|
| 295 |
|
|
| 315 |
|
Long Term REPAT Tax Payable |
|
| 698 |
|
|
| 698 |
|
|
| 698 |
|
|
| 1,256 |
|
Deferred Revenue and Income Taxes |
|
| 208 |
|
|
| 256 |
|
|
| 322 |
|
|
| 628 |
|
Stockholders' Equity |
|
| 124,052 |
|
|
| 127,742 |
|
|
| 128,313 |
|
|
| 121,762 |
|
Total Liabilities & Stockholders' Equity |
| $ | 130,032 |
|
| $ | 135,441 |
|
| $ | 135,458 |
|
| $ | 130,475 |
|
Contact: Brian Koopman (801) 566-1200
SOURCE: Utah Medical Products, Inc.
View the original press release on accesswire.com
FAQ
What were UTMD's revenue figures for the second quarter of 2024?
How did UTMD's 1H 2024 revenues compare to 1H 2023?
What was UTMD's gross profit margin for 2Q 2024?
How much did UTMD spend on share repurchases in 1H 2024?
What were the primary factors for the decline in UTMD's revenues?
What is UTMD's financial outlook for the remaining quarters of 2024?
